Trials / Completed
CompletedNCT00449722
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis
Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (planned)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To proof the therapeutic equivalence of once daily (OD) versus three times daily (TID) dosing of total 3.0 g mesalazine granules in patients with active ulcerative colitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mesalazine |
Timeline
- Start date
- 2005-07-01
- Completion
- 2006-06-01
- First posted
- 2007-03-21
- Last updated
- 2016-01-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00449722. Inclusion in this directory is not an endorsement.